Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:
“I had the pleasure of meeting Matthias Wernicke during his inspiring presentation on the oncology journey at Merck Healthcare.
What impressed me most was the persistence behind every oncology breakthrough — from the development of Cetuximab more than 20 years ago, when targeted therapy was still highly challenging, to today’s era of immunotherapy and precision medicine for rare mutations such as MET exon 14 skipping.
Behind every approval is a long journey of research, challenges, and determination to give patients new hope and better outcomes. This is the true impact of innovation in oncology.”
More posts featuring Rasha Aboelhassan.
